# US 2025/0051321 A1 · Tricyclic derivative and preparation method therefor and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0051321 A1
- Document ID: US20250051321A1
- Status: Published application
- Kind: A1
- Application number: 18/713,633
- Filed: 2022-11-25
- Published: 2025-02-13
- Earliest claimed: 2021-11-25
- Assignees: Shanghai Jemincare Pharmaceutical Co., Ltd.
- Applicants: Shanghai Jemincare Pharmaceutical Co., Ltd.
- Inventors: Gang DENG; Shuchun GUO; Jun FAN; Zhitao ZHANG; Nan WU; Wenqiang SHI; Zhihua FANG; Jianbo FENG; Jianbiao PENG; Haibing GUO
- Web page: https://patentgrep.com/patent/US20250051321A1

## CPC

- A61P 11/00: Drugs for disorders of the respiratory system
- C07D 417/14: containing three or more hetero rings
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/4741: condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- C07D 471/04: Ortho-condensed systems
- C07D 471/10: Spiro-condensed systems
- C07D 471/14: Ortho-condensed systems
- C07D 487/08: Bridged systems
- C07D 487/10: Spiro-condensed systems
- C07D 491/044: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 491/147: the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
- C07D 495/10: Spiro-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07B 2200/07: Optical isomers
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Disclosed are a tricyclic derivative and a preparation method therefor and an application thereof. Specifically, disclosed are a compound shown in formula (I) and an optical isomer thereof or a pharmaceutically acceptable salt thereof, and an application of the compound as an Autotaxin inhibitor.

## Claims

### Claim 1

A compound of formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof,
wherein
ring A is selected from cycloalkyl, heterocyclyl, and heteroaryl;
ring B is selected from cycloalkyl, heterocyclyl, aryl, and heteroaryl;
ring C is selected from aryl and heteroaryl;
ring D is selected from aryl, heteroaryl, cycloalkyl, and heterocyclyl;
X1 is selected from C(R7a) and N;
X2 is selected from C(R7b) and N;
X3 is selected from C(R7c) and N;
X4 is selected from C(R7d) and N;
L1 is selected from a single bond, NR8, O, S, and C1-6 alkyl;
each R1 is independently selected from H, halogen, alkyl, haloalkyl, alkoxy, OH, hydroxyalkyl, cyano, amino, nitro, carboxyl, aldehyde, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
each R2 is independently selected from H, halogen, alkyl, haloalkyl, alkoxy, cyano, amino, nitro, carboxyl, aldehyde, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R3 is selected from H, alkyl, cycloalkyl, and heterocyclyl, wherein the alkyl, cycloalkyl, and heterocyclyl are each independently and optionally substituted by one or more than one substituent selected from halogen, alkyl, alkoxy, cyano, amino, nitro, OH, hydroxyalkyl, carboxyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
each R4 is independently selected from H, halogen, alkyl, haloalkyl, heteroalkyl, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, —COOR9, aryl, and heteroaryl, wherein the alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently and optionally substituted by one or more than one substituent selected from halogen, alkyl, alkoxy, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
each R5 is independently selected from H, halogen, alkyl, haloalkyl, alkoxy, cyano, amino, nitro, carboxyl, aldehyde, OH, hydroxyalkyl, oxo, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently and optionally substituted by one or more than one substituent selected from halogen, alkyl, alkoxy, cyano, amino, nitro, carboxyl, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R6 is -M-L2-Ra;
M is selected from a single bond or alkyl, wherein the alkyl is optionally substituted by one or more than one substituent selected from halogen, alkyl, alkoxy, cyano, amino, nitro, carboxyl, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
L2 is selected from a single bond, —C(═O)—, —C(═O)O—, —C(═O)NRb—, —NRbC(═O)—, —NRbC(═O)O—, —O—, —OC(═O)—, —C(═O)—C(═O)—, —C(═O)—C(═O)NRb—, —NRb—, —S(═O)2—, —S(═O)2NRb—, and —NRbS(═O)2—;
Ra is selected from H, —S(O)2Rc, alkyl, —NRbRc, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently and optionally substituted by one or more than one substituent selected from halogen, alkyl, alkoxy, oxo, cyano, amino, nitro, carboxyl, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
Rb is selected from H, OH, alkyl, haloalkyl, hydroxyalkyl, and cycloalkyl;
Rc is selected from H and alkyl;
R7a, R7b, R7c, and R7d are each independently selected from H, halogen, alkyl, haloalkyl, alkoxy, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl;
R8 is selected from H, alkyl, haloalkyl, hydroxyalkyl, and cycloalkyl;
R9 is selected from H, alkyl, haloalkyl, hydroxyalkyl, and cycloalkyl;
n is 0, 1, 2, 3, or 4;
y is 0, 1, 2, or 3;
m is 0, 1, 2, 3, or 4;
p is 0, 1, 2, or 3.

### Claim 2 (depends on 1)

The compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound of formula (I) is a compound of formula (II),
wherein
q is 0, 1, 2, or 3;
X5 is selected from O, S, N(R4a), C(R4a)2, and C═O;
X6 is selected from O, S, N(R4b), C(R4b)2, and C═O;
each X7 is independently selected from N(R4c), C(R4c)2, and C═O;
represents a double bond or a single bond;
and, when between X5 and X6 represents a double bond, X5 is selected from N and C(R4a), and X6 is selected from N and C(R4b);
and, X6 is not attached to two double bonds simultaneously;
R4a, R4b, and R4c are each independently selected from H, halogen, alkyl, haloalkyl, heteroalkyl, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, —COOR9, aryl, and heteroaryl, wherein the alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each independently and optionally substituted by one or more than one substituent selected from halogen, alkyl, alkoxy, cyano, amino, nitro, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl.

### Claim 3 (depends on 2)

The compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 2, wherein the compound of formula (I) is a compound of formula (III),
wherein
each X8 is independently selected from O, S, N(R2a), —N═CH—, —CH═N—, and —CH═CH;
each X9 is independently selected from C(R2b) and N;
R2a and R2b are each independently selected from H, halogen, alkyl, haloalkyl, alkoxy, cyano, amino, nitro, carboxyl, aldehyde, OH, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl.

### Claim 4 (depends on 1)

The compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein ring A is selected from C4-8 cycloalkyl, 4- to 8-membered heterocyclyl, and 5- to 6-membered heteroaryl;
or, each R4 is independently selected from H, OH, C1-6 alkyl, and C1-6 heteroalkyl, wherein the C1-6 alkyl and C1-6 heteroalkyl are optionally substituted by one or more than one of OH, amino, and halogen;
or, ring B is selected from phenyl, 5- to 6-membered heteroaryl, C3-6 cycloalkyl, 5- to 6-membered heterocyclyl, benzo-5- to 6-membered heterocyclyl, and 5- to 9-membered bicycloalkyl;
or, ring D is selected from phenyl, 5- to 6-membered heteroaryl, C3-6 cycloalkyl, and 6- to 10-membered heterocyclyl;
or, R6 is selected from —C1-3 alkyl-C(═O)-3- to 9-membered heterocyclyl, —C1-3 alkyl-C(═O)-3- to 9-membered heterocyclyl-C1-6 alkyl, —C(═O)-3- to 9-membered heterocyclyl, —C(═O)—C3-9 cycloalkyl, —C(═O)—C1-6 alkyl, —C1-3 alkyl-C(═O)—NH—C1-6 alkyl, —S(═O)2—C1-3 alkyl, and —C1-3 alkyl-C(═O)NH—OH, wherein the —C1-3 alkyl-C(═O)-3- to 9-membered heterocyclyl, —C1-3 alkyl-C(═O)-3- to 9-membered heterocyclyl-C1-6 alkyl, —C(═O)-3- to 9-membered heterocyclyl, —C(═O)—C3-9 cycloalkyl, —C(═O)—C1-6 alkyl, —C1-3 alkyl-C(═O)—NH—C1-6 alkyl, —S(═O)2—C1-3 alkyl, or —C1-3 alkyl-C(═O)NH—OH is optionally substituted by 1, 2, or 3 OH, amino, methyl, ethyl, hydroxymethyl, trifluoromethyl, methoxy, or halogens;
or, R3 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and 4- to 6-membered heterocyclyl, wherein the C1-6 alkyl, C3-6 cycloalkyl, or 4- to 6-membered heterocyclyl is optionally substituted by 1, 2, or 3 halogens, cyano, amino, or C1-6 alkyl;
or, ring C is selected from 5- to 6-membered heteroaryl, wherein the heteroaryl comprises 1 to 3 heteroatoms selected from N atom, O atom, or S atom;
or, R7a, R7b, R7c, and R7d are each independently selected from H, halogen, C1-6 alkyl, C1-6 alkoxy, cyano, amino, nitro, OH, C3-6 cycloalkyl, 5- to 6-membered heterocyclyl, phenyl, and 5- to 6-membered heteroaryl, wherein the C1-6 alkyl is optionally substituted by 1, 2, or 3 halogens.

### Claim 5 (depends on 1)

The compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein ring A is selected from C4-6 cycloalkyl, 5- to 6-membered heterocyclyl, and 5- to 6-membered heteroaryl;
or, ring B is selected from phenyl, pyridyl, cyclohexyl, tetrahydro-2H-pyranyl, benzo[d][1,3]dioxazolyl, and bicyclo[1.1.1]pentyl;
or, ring D is selected from piperazinyl, 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[4.4]nonyl, 2,8-diazaspiro[4.5]decyl, 2,7-diazaspiro[3.5]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, and octahydropyrrolo[3,4-c]pyrrolyl;
or, R6 is selected from
is optionally substituted by 1, 2, or 3 OH, methyl, ethyl, hydroxymethyl, or halogens
or, R3 is selected from H, methyl, ethyl,

### Claim 6 (depends on 1)

The compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein ring A is selected from cyclobutyl, cyclopentyl, tetrahydrofuranyl, pyrrolidinyl, cyclopentanone, dihydrofuran-2(3H)-one, pyrrolidin-2-one, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, and 1,2,3-oxadiazolyl
or, ring D is selected from
or, R6 is selected from

### Claim 7

(canceled)

### Claim 8 (depends on 2)

The compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 2, wherein R4a, R4b, and R4c are each independently selected from H, OH, C1-6 alkyl, and C1-6 heteroalkyl, wherein the C1-6 alkyl and C1-6 heteroalkyl are optionally substituted by one or more than one of OH, amino, and halogen.

### Claim 9 (depends on 1)

The compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein structural moiety
is selected from
or, structural moiety
is selected from
and
or, structural moiety
is selected from

### Claim at position 10

10-23. (canceled)

### Claim 24 (depends on 1)

The compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein structural moiety
is selected from

### Claim 25 (depends on 1)

The compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1, wherein structural moiety
is selected from

### Claim 26

A compound of the following formulas, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, selected from:

### Claim 27

A compound of the following formulas, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, selected from:

### Claim 28 (depends on 1)

A method of treating a disease related to ATX in a subject in need thereof, comprising administering a therapeutically effective amount of the compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the disease related to ATX is selected from cancer, metabolic disease, renal disease, liver disease, fibrotic disease, inflammatory disease, pain, autoimmune disease, respiratory disease, cardiovascular disease, neurodegenerative disease, myelodysplastic syndrome, obesity, dermatological disorder, or disease related to abnormal angiogenesis.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the disease related to ATX is selected from pulmonary fibrosis, renal fibrosis, and hepatic fibrosis;
or, the liver disease is non-alcoholic steatohepatitis;
or, the inflammatory disease is selected from enteritis and osteoarthritis;
or, the autoimmune disease is selected from rheumatoid arthritis and multiple sclerosis;
or, the respiratory disease is selected from interstitial lung disease, asthma, and COPD;
or, the cardiovascular disease is selected from vascular injury, atherosclerosis, and coagulation.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the pulmonary fibrosis is selected from idiopathic pulmonary fibrosis and non-idiopathic pulmonary fibrosis.

### Claim at position 19

32-36. (canceled)
